Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Test entities : Biodesix, inc. save search
Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules
Published: 2023-07-12 (Crawled : 12:00) - biospace.com/
BDSX | $1.23 1.65% 12K
|
Health Services
|
| O: 4.27%
H: 4.92%
C: -3.69%
xl2 lung test publication study
Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference
Published: 2023-05-18 (Crawled : 12:20) - biospace.com/
BDSX | $1.23 1.65% 12K
|
Health Services
|
| O: -1.65%
H: 4.2%
C: -4.2%
xl2 conference test international risk
HIROTSU BIO SCIENCE INC.: World's First Test for Early-Stage Pancreatic Cancer, "N-NOSE® plus Pancreas", Now Available HIROTSU BIO SCIENCE INC. is pleased to announce the commercialization of "N-NOSE p...
Published: 2022-11-17 (Crawled : 13:00) - biospace.com/
TCDA | $0.108 -22.22% 0
|
Health Technology
|
| O: -1.38%
H: 0.0%
C: 0.0%
MRNS | $1.37 -4.86% 1.8M
|
Health Technology
|
| O: -1.09%
H: 3.96%
C: -1.1%
BDSX | $1.23 1.65% 12K
|
Health Services
|
| O: 0.87%
H: 24.14%
C: 22.41%
nose test commercialization plus pancreatic
Biodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participating in Lung Cancer Screening Programs
Published: 2022-10-12 (Crawled : 11:00) - biospace.com/
BDSX | $1.23 1.65% 12K
|
Health Services
|
| O: 3.94%
H: 4.55%
C: -10.61%
xl2 lung test meeting cancer
Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors
Published: 2022-07-20 (Crawled : 11:00) - biospace.com/
BDSX | $1.23 1.65% 12K
|
Health Services
|
| O: 0.56%
H: 5.62%
C: 1.69%
veristrat conference test negative
Biodesix Obtains Medicare Coverage for the Nodify CDT® Lung Nodule Test
Published: 2022-06-07 (Crawled : 11:00) - biospace.com/
BDSX | $1.23 1.65% 12K
|
Health Services
|
| O: 10.71%
H: 34.19%
C: 15.48%
cdt test
Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to be Presented at ATS 2022 International Conference
Published: 2022-05-12 (Crawled : 11:00) - biospace.com/
BDSX | $1.23 1.65% 12K
|
Health Services
|
| O: -11.18%
H: 12.58%
C: 6.29%
xl2 risk conference test international
Biodesix Announces Impactful Clinical Data on the Primary Immune Response (PIR) Test at the IASLC 2022 Therapies of Lung Cancer Meeting
Published: 2022-03-03 (Crawled : 12:00) - biospace.com/
BDSX | $1.23 1.65% 12K
|
Health Services
|
| O: 2.11%
H: 3.31%
C: -5.79%
ces response lung cancer test pons cancer
Biodesix Announces the Launch of its GeneStrat NGS™ Test and the IQLung™ Testing Strategy with Unprecedented Time to Results
Published: 2022-01-18 (Crawled : 12:00) - biospace.com/
BDSX | $1.23 1.65% 12K
|
Health Services
|
| O: -0.42%
H: 3.15%
C: -9.87%
test
Biodesix Announces Publication Highlighting Interim Data from the INSIGHT Study Assessing the Clinical Effectiveness of VeriStrat® Proteomic Test in the Journal of Immunotherapy of Cancer
Published: 2021-11-18 (Crawled : 12:00) - biospace.com/
BDSX | $1.23 1.65% 12K
|
Health Services
|
| O: -0.76%
H: 0.0%
C: -0.92%
veristrat immunotherapy test therapy cancer
Biodesix to Present Data Supporting Proteomic-Based Immunotherapy Diagnostic Tests and AI Explainability in Diagnostic Tests at Society for Immunotherapy of Cancer Annual Meeting
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
BDSX | $1.23 1.65% 12K
|
Health Services
|
| O: -1.5%
H: 0.0%
C: 0.0%
immunotherapy test therapy cancer diagnostic
Biodesix Announces New Data on Nodify Lung® Nodule Risk Assessment Testing at the CHEST 2021 Annual Meeting
Published: 2021-10-13 (Crawled : 11:00) - biospace.com/
BDSX | $1.23 1.65% 12K
|
Health Services
|
| O: -2.09%
H: 7.46%
C: 5.54%
risk test
Biodesix Announces Commercial Availability of SARS CoV-2 Neutralization Antibody Test
Published: 2021-06-15 (Crawled : 12:00) - biospace.com/
BDSX | $1.23 1.65% 12K
|
Health Services
|
| O: 0.37%
H: 1.49%
C: -3.04%
test antibody sars-cov-2 commercialization
Biodesix Announces Intent to Launch Liquid Biopsy Next Generation Sequencing Test with Unprecedented Turnaround Time
Published: 2021-04-28 (Crawled : 14:00) - biospace.com/
BDSX | $1.23 1.65% 12K
|
Health Services
|
| O: -0.24%
H: 8.03%
C: 2.96%
test
Biodesix Publishes Extended Analyses of the Nodify XL2® Lung Nodule Test
Published: 2020-12-01 (Crawled : 22:01) - biospace.com/
BDSX | $1.23 1.65% 12K
|
Health Services
|
| O: 0.0%
H: 0.2%
C: -12.49%
test
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
TIRX | $1.13 133.09% 44M
|
AGBA | $0.8978 124.45% 60M
|
Finance
BPTH | $6.18 90.74% 39M
|
Health Technology
INVO | $1.44 89.47% 3M
|
Health Technology
XPON | $2.66 37.82% 5.2M
|
SINT | $0.0504 35.12% 300M
|
Health Technology
THCH | $1.38 32.69% 9.9M
|
n/a
ALRN | $5.605 31.88% 210K
|
Health Technology
HOLO | $2.92 30.36% 22M
|
VTNR S | $1.25 27.66% 3.2M
|
Industrial Services
Your saved searches
Save your searches and get alerts when important news are released.